Rankings
▼
Calendar
▼
MBX Q3 2023 Earnings Report — MBX Biosciences, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
MBX Biosciences, Inc. Common Stock
MBX
Q3 2023 Earnings
Reported September 30, 2023
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q3 2023
Q2 2023
Q3 2022
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$11M
-$8M
—
-36.7%
—
EPS (Diluted)
$-0.32
$-0.23
—
-39.1%
—
Free Cash Flow
-$8M
-$7M
—
-4.5%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$9M
Selling & Marketing
$0
General & Administrative
$2M
SG&A Expenses
$2M
Other Expenses
$0
Operating Expenses
$11M
Cost & Expenses
$11M
OPERATING INCOME
-$11M
Interest Income
$783.0K
Interest Expense
$0
Other Income/Expenses
$783.0K
INCOME BEFORE TAX
-$10M
Income Tax Expense
$0
Net Income from Continuing Ops
-$10M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$10M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$10M
D&A
$40.0K
EBIT
-$11M
EBITDA
-$11M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$10M
Depreciation & Amortization
$40.0K
Stock-Based Compensation
$596.0K
Deferred Income Tax
$0
Other Non-Cash Items
$9.0K
Change in Working Capital
$2M
OPERATING CASH FLOW
-$8M
Capital Expenditure
-$22.0K
Acquisitions (Net)
$0
Purchases of Investments
-$21M
Sales/Maturities of Investments
$2M
Other Investing Activities
$0
NET CASH FROM INVESTING
-$19M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$68M
FREE CASH FLOW
-$8M
Net Change in Cash
$42M
marketcaparena.com
← FY 2023
MBX Overview
Q4 2023 →